Comparison of Citalopram and Metacognitive Therapy on Depression in Patients with Major Depressive Disorder

Document Type : Original Article (s)

Authors

1 Associate Professor, Behavioral Sciences Research Center AND Department of Psychiatry, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

2 Resident, Behavioral Sciences Research Center AND Department of Psychiatry, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

3 Assistant Professor, Department of Psychology, School of Literature and Humanities, Salman Farsi University of Kazerun, Kazerun, Iran

4 Assistant Professor, Department of Emergency Medicine, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

5 Professor, Department of Biostatistics and Epidemiology, School of Public Health, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: Major depressive disorder (MDD) is a prevalent and devastating psychiatric disorder worldwide that needs multidimensional interventions. Metacognitive treatment is a new psychotherapeutic approach of some psychiatric disorders. This study was conducted to comparatively evaluate the impact of citalopram and metacognitive interventions on major depressive disorder.Methods: This was a clinical trial study with a pretest/posttest design. After selection of objects, the eligible patients were randomly assigned into three groups of citalopram (n = 12), metacognitive intervention (n = 16), and waiting list (n = 8). One experimental group received ten 1-houre sessions of metacognitive therapy; 10-40 mg citalopram was administered to other group; and third group did not receive any interventions and placed on waiting list. Outcome measures were done using Beck Depression Inventory (BDI), Metacognitions Questionnaire-30 (MCQ30), and Cognitive Emotion Regulation Questionnaire (CERQ) before and after interventions. Data analysis was performed using ANOVA and post hoc tests.Findings: There was significant difference between the groups in terms of symptom of depression, metacognition, and emotion regulation before and after intervention. In term of metacognition, only metacognitive therapy was useful (P = 0.010). Symptom of depression were improved significantly with metacognitive therapy (P = 0.007); but in pharmacotherapy, despite clinical improvement, there was not any statistically significant improvement (P = 0.070). In addition, emotion regulation was improved with metacognitive therapy (P = 0.020).Conclusion: Metacognitive therapy could be used in major depressive disorder. In addition, this intervention could lead to higher level of cognitive emotion regulation.

Keywords

References

  1. Kaviani H, Ahmadi Abhari AS, Nazari H, Hormozi K. Prevalence of depressive disordrs in Tehran resident population (year 2000). Tehran Univ Med J 2002; 60(5): 393-9. [In Persian].
  2. Gotlib IH, Joormann J. Cognition and depression: current status and future directions. Annu Rev Clin Psychol 2010; 6: 285-312.
  3. Calkins SD. Commentary: Conceptual and methodological challenges to the study of emotion regulation and psychopathology. J Psychopathol Behav Assess 2010; 32(1): 92-5.
  4. Nolen-Hoeksema S. Emotion regulation and psychopathology: The role of gender. Annu Rev Clin Psychol 2012; 8: 161-87.
  5. Wells A, Matthews G. Attention and emotion: A clinical perspective. Hove, UK: Lawrence Erlbaum; 1994.
  6. Wisco BE. Depressive cognition: Self-reference and depth of processing. Clin Psychol Rev 2009; 29(4): 382-92.
  7. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006; 163(11): 1905-17.
  8. Brosen K, Naranjo CA. Review of pharmacokinetic and pharmacodynamic interaction studies with citalopram. Eur Neuropsychopharmacol 2001; 11(4): 275-83.
  9. Wells A. Metacognitive therapy for anxiety and depression. New York, NY: Guilford Press; 2008.
  10. Fisher P, Wells A. Metacognitive therapy: Distinctive features. New York, NY: Routledge; 2009.
  11. Papageorgiou C, Wells A. Metacognitive beliefs about rumination in recurrent major depression. Cogn Behav Pract 2001; 8(2): 160-4.
  12. Papageorgiou C, Wells A. An empirical test of a clinical metacognitive model of rumination and depression. Cognitive Ther Res 2003; 27(3): 261-73.
  13. Simmons KL, Smith JA, Bobb KA, Liles LL. Adjustment to colostomy: stoma acceptance, stoma care self-efficacy and interpersonal relationships. J Adv Nurs 2007; 60(6): 627-35.
  14. Dabson KS, MOhammad Khani P. Psychometric characteristics of Beck Depression Inventory–II in patients with major depressive disorder. Journal of Rehabilitation 2007; 8(2): 82-8.
  15. Dargahian R, Mohammadkhani S, Hasani J. The efficacy of metacognitive therapy on depression symptoms reduction, cognitive attentional syndrome components and maladaptive coping styles in patients with major depression. Shefaye Khatam 2014; 2(3): 45-52. [In Persian].
  16. Rabie M, Zerehpush A, Palahang H, Zarie Mahmood Abadi H. Relationship between components of cognitive emotion regulation and anxiety disorders. J Res Behave Sci 2014; 11(5): 363-74. [In Persian].
  17. Chapman DP, Perry GS. Depression as a major component of public health for older adults. Prev Chronic Dis 2008; 5(1): A22.
  18. Gertsik L, Poland RE, Bresee C, Rapaport MH. Omega-3 fatty acid augmentation of citalopram treatment for patients with major depressive disorder. J Clin Psychopharmacol 2012; 32(1): 61-4.
  19. Apler A. Citalopram for major depressive disorder in adults: A systematic review and meta-analysis of published placebo-controlled trials. BMJ Open 2011; 1(2): e000106.
  20. Ritchey M, Dolcos F, Eddington KM, Strauman TJ, Cabeza R. Neural correlates of emotional processing in depression: changes with cognitive behavioral therapy and predictors of treatment response. J Psychiatr Res 2011; 45(5): 577-87.
  21. Fu CH, Steiner H, Costafreda SG. Predictive neural biomarkers of clinical response in depression: a meta-analysis of functional and structural neuroimaging studies of pharmacological and psychological therapies. Neurobiol Dis 2013; 52: 75-83.
  22. Johnson SL, Joormann J, Gotlib IH. Does processing of emotional stimuli predict symptomatic improvement and diagnostic recovery from major depression? Emotion 2007; 7(1): 201-6.
  23. Callesen P, Jensen AB, Wells A. Metacognitive therapy in recurrent depression: a case replication series in Denmark. Scand J Psychol 2014; 55(1): 60-4.
  24. Jordan J, Carter JD, McIntosh VV, Fernando K, Frampton CM, Porter RJ, et al. Metacognitive therapy versus cognitive behavioural therapy for depression: a randomized pilot study. Aust N Z J Psychiatry 2014; 48(10): 932-43.
  25. Watkins ER, Mullan E, Wingrove J, Rimes K, Steiner H, Bathurst N, et al. Rumination-focused cognitive-behavioural therapy for residual depression: phase II randomised controlled trial. Br J Psychiatry 2011; 199(4): 317-22.
  26. Nolen-Hoeksema S, Stice E, Wade E, Bohon C. Reciprocal relations between rumination and bulimic, substance abuse, and depressive symptoms in female adolescents. J Abnorm Psychol 2007; 116(1): 198-207.
  27. Aldao A, Nolen-Hoeksema S. Specificity of cognitive emotion regulation strategies: a transdiagnostic examination. Behav Res Ther 2010; 48(10): 974-83.
  28. Reynolds M, Wells A. The Thought Control Questionnaire--psychometric properties in a clinical sample, and relationships with PTSD and depression. Psychol Med 1999; 29(5): 1089-99.
  29. Zemestani M, Davoudi I, Mehrabizadeh Honarmand M, Zargar Y. effectiveness of group behavioral activation on depression, anxiety and rumination in patients with depression and anxiety. Journal of Clinical Psychology 2014; 5(4): 73-84. [In Persian].
Journal of Isfahan Medical School
Volume 35, Issue 447 - Serial Number 447
July and August 2017
Pages 1242-1248

Files

History

  • Receive Date: 03 May 2017
  • Revise Date: 02 May 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics